Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 18Terminated 5Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × brivanib × Clear all
NCT04395612 2021-05-21

CQGOG0101

Chongqing University Cancer Hospital

Phase 2 Unknown
38 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03895788 2019-03-29

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Hunan Cancer Hospital

Phase 1 Unknown
24 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡